2-[2-(acetylamino)-4-(diethylamino)-5-methoxyphenyl]-5-amino-7-bromo-4-chloro-2H-benzotriazole | 468062-49-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[2-(acetylamino)-4-(diethylamino)-5-methoxyphenyl]-5-amino-7-bromo-4-chloro-2H-benzotriazole
• 英文别名: 2-[2-(Acetylamino)-4-(diethylamino)-5-methoxyphenyl]-5-amino-7-bromo-4-chloro-2h-benzotriazole；N-[2-(5-amino-7-bromo-4-chlorobenzotriazol-2-yl)-5-(diethylamino)-4-methoxyphenyl]acetamide
• CAS: 468062-49-9
• 化学式: C₁₉H₂₂BrClN₆O₂
• 分子量: 481.78
• InChiKey: RXJPIXOLVXIWMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  98.3
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-[2-(acetylamino)-4-(diethylamino)-5-methoxyphenyl]-6-amino-4-bromo-2H-benzotriazole 在 sodium hypochlorite 作用下， 以 二氯甲烷 为溶剂， 反应 0.08h， 以72%的产率得到2-[2-(acetylamino)-4-(diethylamino)-5-methoxyphenyl]-5-amino-7-bromo-4-chloro-2H-benzotriazole
  参考文献：
  名称：

  Watanabe, Tetsushi; Shiozawa, Tatsushi; Takahashi, Yoshifumi, Mutagenesis, 2002, vol. 17, # 4, p. 293 - 299

  摘要：

  DOI：

文献信息

• Methods and compositions for extending lifespan
  申请人：Longevica Therapeutics Inc.

  公开号：US10653715B2

  公开（公告）日：2020-05-19

  The present invention relates to methods for attenuating aging, of health maintenance, and/or treating, or delaying the onset of, an age-related condition or disorder, in a subject comprising administering to the subject an effective amount of (a) one or more compounds that sustain pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion and (b) one or more chelators. A further aspect of the invention is a composition comprising (a) and (b).

  本发明涉及减轻受试者衰老、维持健康和/或治疗与年龄有关的疾病或紊乱或推迟其发生的方法，包括向受试者施用有效量的(a)一种或多种化合物，这些化合物可持续药理激活异生物代谢或诱导肠道细菌发酵以产生激活异生物代谢酶和/或刺激异生物排泄的物质；以及(b)一种或多种螯合剂。本发明的另一方面是一种包含(a)和(b)的组合物。
• METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES
  申请人：Longevica Therapeutics Inc.

  公开号：US20180256617A1

  公开（公告）日：2018-09-13

  The present disclosure relates to methods of extending the lifespan of a subject or treating, suppressing, inhibiting or delaying the onset of an age-related condition or disorder, such as cancer, in a subject. The methods comprise administering to the subject an effective amount of (i) a compound that sustains pharmacological activation of xenobiotic metabolism, (ii) a cardiac glycoside, (iii) a chelator, (iv) inulin, (v) D-valine, or any combination thereof. In a further aspect, the present disclosure relates to a method of identifying clinical candidates by performing a high throughput screening in mammals of test compounds which have great structural and/or functional diversity.
• METHODS AND COMPOSITIONS FOR EXTENDING LIFESPAN
  申请人：Longevica Therapeutics Inc.

  公开号：US20200254006A1

  公开（公告）日：2020-08-13

  The present invention relates to methods for attenuating aging, of health maintenance, and/or treating, or delaying the onset of, an age-related condition or disorder, in a subject comprising administering to the subject an effective amount of (a) one or more compounds that sustain pharmacological activation of xenobiotic metabolism or induce fermentation by gut bacteria to produce substances that activate xenobiotic metabolism enzymes and/or stimulate xenobiotic excretion and (b) one or more chelators. A further aspect of the invention is a composition comprising (a) and (b).
• [EN] METHODS FOR EXTENDING LIFESPAN AND METHODS OF SCREENING KNOWN PHARMACOLOGICAL AGENTS FOR NEW USES<br/>[FR] PROCÉDÉS D'EXTENSION DE LA DURÉE DE VIE ET PROCÉDÉS DE CRIBLAGE D'AGENTS PHARMACOLOGIQUES POUR NOUVELLES UTILISATIONS
  申请人：LONGEVICA THERAPEUTICS INC

  公开号：WO2016168670A2

  公开（公告）日：2016-10-20

  The present disclosure relates to methods of extending the lifespan of a subject or treating, suppressing, inhibiting or delaying the onset of an age-related condition or disorder, such as cancer, in a subject. The methods comprise administering to the subject an effective amount of (i) a compound that sustains pharmacological activation of xenobiotic metabolism, (ii) a cardiac glycoside, (iii) a chelator, (iv) inulin, (v) D-valine, or any combination thereof. In a further aspect, the present disclosure relates to a method of identifying clinical candidates by performing a high throughput screening in mammals of test compounds which have great structural and/or functional diversity.